Spain · Investor

Ysios Capital

Last cheque observed Sep 2026; 35 cheques on record.

Deploying nowVC firm

SeedSeries ASeries BBankingFunding PlatformVenture Capital & Private Equity

Deploying now
100%of best year2cheques in 12 months, 35 on record
Since the last cheque38days00hrs00min00sec
Median round$33MCheque size, as they say$1.0M – $7.5MRounds led0 of 35Sole investor3 roundsExits2 from the portfolioMostly inSpain, 45%
Pitch Ysios Capital

Ysios Capital highlights

  1. 01

    2 cheques in the last 12 months

  2. 02

    Mostly Series B and Series A: 63% of its rounds

  3. 03

    Sole investor in 3 rounds, median $2.8M

  4. 04

    2 exits from the portfolio

What they do

Type
VC firm (from a list, unverified)
Cheque size
$1.0M – $7.5M as they say
Stages
SeedSeries ASeries BGrowthPre-IPO
Sectors
BankingFunding PlatformVenture Capital & Private Equity
Based in
San Sebastian, Spain
Cold pitches
Not stated

The record

Every round we can evidence, newest first35 appearances

  1. 2026

    2 rounds

  2. Sept
    Anaconda BiomedSeries C · ES · Asabys$56MWith 5 others
  3. Jun
    Ona TherapeuticsSeries B · ES · Asabys$87MWith 11 others
  4. 2019

    2 rounds

  5. Dec
    AnacondaSeries B · ES · FinSMEs$22MWith 4 others
  6. Jul
    AM-PharmaNL · FinSMEs$130MWith 7 others
  7. 2018

    3 rounds

  8. Oct
    GalectoSeries C · DK · FinSMEs$90MWith 9 others
  9. Sept
    MinoryxSeries B · ES · FinSMEs$25MWith 9 others
  10. May
    BioClinSeries B · FinSMEs$20MWith 6 others
  11. 2017

    5 rounds

  12. Dec
    Aura BiosciencesSeries C · US · 4-traders$30MWith 9 others
  13. Nov
    XeltisSeries C · CH · FinSMEs$53MSole investor
  14. May
    Anaconda BiomedSeries A · ES · FinSMEs$17MWith 3 others
  15. Mar
    MedLumicsSeries B · ES · FinSMEs$37MWith 2 others
  16. Feb
    Prexton TherapeuticsSeries B · CH · FinSMEs$31MWith 4 others
  17. 2016

    2 rounds

  18. Nov
    OxTheraSE · FinSMEs$34MWith 3 others
  19. Sept
    Aura BiosciencesUS · FinSMEs$8.0MWith 2 others
  20. 2015

    4 rounds

  21. Oct
    Minoryx TherapeuticsSeries A · ES$22MWith 6 others
  22. Sept
    SANIFITSeries C · ES$41MWith 6 others
  23. Mar
    Aura BiosciencesSeries B · US$21MWith 4 others
  24. Feb
    Prexton TherapeuticsSeries A · CH$10MWith 2 others
  25. 2014

    2 rounds

  26. Sept
    AM PharmaSeries E · NL$16MWith 5 others
  27. Apr
    Kala PharmaceuticalsSeries B · US$23MWith 5 others
  28. 2013

    3 rounds

  29. Dec
    AcousticeyeVenture · NL · finsmes.com$7.0MWith 3 others
  30. Oct
    CVRxSeries F · US · finsmes.com$12MWith 1 other
  31. Oct
    Series A · sec.gov$2.7MWith 10 others
  32. 2012

    2 rounds

  33. Nov
    EndosenseSeries C · CH · finsmes.com$40MWith 7 others
  34. Jun
    InbiomotionSeries A · ES · pevc.dowjones.com$2.5MSole investor
  35. 2011

    3 rounds

  36. Dec
    MedlumicsSeries A · ES · finsmes.com$4.7MWith 1 other
  37. Sept
    AM PharmaSeries D · NL · am-pharma.com$40MWith 3 others
  38. Jun
    STAT-DiagnosticaSeries A · ES · finsmes.com$2.8MSole investor
  39. 2010

    3 rounds

  40. Sept
    CardozSeries A · SE · finsmes.com$18MWith 3 others
  41. Sept
    SabirmedicalVenture · ES · finsmes.com$6.5MWith 1 other
  42. Jan
    CellerixSeries C · ES · onbiovc.com$38MWith 5 others
  43. 2009

    3 rounds

  44. Nov
    CellerixSeries B · ES · cellerix.com$41MWith 5 others
  45. Nov
    BioVexSeries F · GB · xconomy.com$30MWith 4 others
  46. Oct
    EndosenseSeries B · CH · onbiovc.com$36MWith 6 others
  47. 2007

    1 round

  48. Sept
    CellerixSeries B · ES · fiercebiotech.com$37MWith 4 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 12 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

Exits from the portfolio

Companies it backed that were later bought or listed2 in all

EndosenseBought by St. Jude Medical$170MAug 2013
BioVexBought by Amgen$1.0BJan 2011

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Ysios Capital. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Ysios Capital put money into.

Quick answers about Ysios Capital

What does Ysios Capital invest in?

Ysios Capital invests most often at Series B and Series A (63% of the rounds on record), in sectors such as Banking, Funding Platform and Venture Capital & Private Equity.

How active is Ysios Capital?

35 investments on record, 2 of them in the last 12 months. The most recent was in Sept 2026.

What has Ysios Capital invested in recently?

Its most recent investments on record: Anaconda Biomed (Series C, Sept 2026), Ona Therapeutics (Series B, Jun 2026) and Anaconda (Series B, Dec 2019).

How big are Ysios Capital's cheques?

The median round it joins is $33M. It says it writes cheques of $1.0M to $7.5M.

Does Ysios Capital lead rounds?

Rarely, if at all: none of its 35 investments on record names it as the lead.

Where does Ysios Capital invest?

Most of the companies it backs are in Spain (45%), the United States (15%) and Switzerland (15%).

Is Ysios Capital investing now?

Yes: it is actively investing, with 2 investments in the last 12 months.

Who does Ysios Capital invest alongside?

Most often Chiesi Ventures (5 rounds together), Forbion Capital Partners (4 rounds together) and Idinvest Partners (4 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it